1) Dyck PJ, Low PA, Windebank AJ, et al:Plasma exchange in polyneuropathy associated with monoclonal gammopathy of undetermined significance. N Engl J Med 1991;325:1482-6 2) Lunn MP, Nobile-Orazio E:Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies. Cochrane Database Syst Rev 2006;CD002827 3) Lunn MP, Nobile-Orazio E:Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies. Cochrane Database Syst Rev 2016;10:CD002827 4) Dalakas MC, Rakocevic G, Salajegheh M, et al:Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy. Ann Neurol 2009;65:286-93 5) Nobile-Orazio E, Meucci N, Baldini L, et al:Long-term prognosis of neuropathy associated with anti-MAG IgM M-proteins and its relationship to immune therapies. Brain 2000;123(Pt 4):710-7 6) Oksenhendler E, Chevret S, Leger JM, et al:Plasma exchange and chlorambucil in polyneuropathy associated with monoclonal IgM gammopathy. IgM-associated Polyneuropathy Study Group. J Neurol Neurosurg Psychiatry 1995;59:243-7 7) Vallat JM, Magy L, Ciron J, et al:Therapeutic options and management of polyneuropathy associated with anti-MAG antibodies. Expert Rev Neurother 2016;16:1111-9 8) Gorson KC, Ropper AH, Weinberg DH, Weinstein R:Treatment experience in patients with anti-myelin-associated glycoprotein neuropathy. Muscle Nerve 2001;24(6):778-86 9) Allen D, Lunn MP, Niermeijer J, Nobile-Orazio E:Treatment for IgG and IgA paraproteinaemic neuropathy. Cochrane Database Syst Rev 2007;CD005376 10) Joint Task Force of the E, the PNS:European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of paraproteinemic demyelinating neuropathies. Report of a Joint Task Force of the European Federation of Neurological Societies and the Peripheral Nerve Society―first revision. J Peripher Nerv Syst 2010;15:185-95 11) Simmons Z, Albers JW, Bromberg MB, Feldman EL:Long-term follow-up of patients with chronic inflammatory demyelinating polyradiculoneuropathy, without and with monoclonal gammopathy. Brain 1995;118(Pt 2):359-68 12) Gorson KC, Allam G, Ropper AH:Chronic inflammatory demyelinating polyneuropathy:clinical features and response to treatment in 67 consecutive patients with and without a monoclonal gammopathy. Neurology 1997;48:321-8